Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €1.25 EUR
Change Today +0.017 / 1.38%
Volume 0.0
VPA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 6:33 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

aveo pharmaceuticals inc (VPA) Snapshot

Open
€1.25
Previous Close
€1.24
Day High
€1.25
Day Low
€1.23
52 Week High
03/6/15 - €1.85
52 Week Low
12/11/14 - €0.46
Market Cap
65.3M
Average Volume 10 Days
1.2K
EPS TTM
--
Shares Outstanding
52.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AVEO PHARMACEUTICALS INC (VPA)

aveo pharmaceuticals inc (VPA) Related Businessweek News

No Related Businessweek News Found

aveo pharmaceuticals inc (VPA) Details

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development include Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has completed Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study. The company’s development programs also comprise AV-380 Program, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia, which is a multi-factorial syndrome of involuntary weight loss associated with various cancers and diseases outside of cancer. It has strategic partnerships with Ophthotech Corporation; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec Inc.; and Kyowa Hakko Kirin. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

57 Employees
Last Reported Date: 03/6/15
Founded in 2001

aveo pharmaceuticals inc (VPA) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $351.1K
Executive Officer
Total Annual Compensation: $334.5K
Chief Financial Officer
Total Annual Compensation: $350.9K
Compensation as of Fiscal Year 2013.

aveo pharmaceuticals inc (VPA) Key Developments

AVEO Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

AVEO Pharmaceuticals, Inc. announced unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported collaboration revenue of $0.115 million against $0.323 million a year ago. Loss from operations was $12.993 million against $16.069 million a year ago. Net loss was $13.894 million or $0.27 per basic and diluted share against $16.725 million or $0.32 per basic and diluted share a year ago. For the year, the company reported collaboration revenue of $18.123 million against $1.293 million a year ago. Loss from operations was $50.449 million against $103.904 million a year ago. Net loss was $52.739 million or $1.01 per basic and diluted share against $107.029 million or $2.10 basic and per diluted share a year ago. The decrease in revenue was primarily due to recognition of an additional $13.7 million of previously deferred revenue as a result of the modification of the company’s arrangement with Biogen Idec. In addition, the company recognized an additional $3.1 million of collaboration revenue in connection with the change in the estimated period of performance associated with the company’s collaboration with Astellas as a result of the termination of the agreement in August 2014.

AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS with Tivozanib Compared to Bevacizumab in Low Serum NRP-1 Patients with Advanced CRC

AVEO Oncology announced the presentation of final results, including a predefined biomarker analysis, from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer (CRC). The presentation, titled â Neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib + mFOLFOX6 versus bevacizumab + mFOLFOX6 in metastatic colorectal cancer: post-hoc biomarker analysis of BATON-CRC Phase 2 trial,â will be presented in a poster session at the American Association for Cancer Research (AACR) Tumor Angiogenesis and Vascular Normalization Conference, taking place March 5-8, 2015, in Orlando, FL. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a long half-life and activity against all three VEGF receptors. The BATON-CRC study enrolled a total of 265 patients randomized 2 to 1 to receive tivozanib in combination with mFOLFOX6 (n=177) compared to bevacizumab and mFOLFOX6 (n=88) as first-line treatment in patients with advanced metastatic CRC. A key objective of the BATON-CRC study is the assessment of prospectively defined biomarkers that may be predictive of response in selected patient subpopulations. Among these, patients with low neuropilin-1 (NRP-1) showed an improved progression free survival (PFS) versus patients with high NRP-1 in both treatment arms, supporting the value of NRP-1 as a potential prognostic marker for angiogenesis inhibitors. Further, patients with serum NRP-1 levels below the median demonstrated longer PFS when treated with tivozanib (17.9 months, n=52), compared to bevacizumab (11.2 months, n=28) (HR=0.380, p=0.0075), suggesting NRP-1 may have potential as a predictive biomarker of tivozanib activity relative to bevacizumab. Patients with high serum NRP-1 had PFS of 7.3 months and 7.5 months for the tivozanib and bevacizumab arms, respectively. With only 21 deaths in the NRP-1 low group upon study termination, no conclusion could be reached in an analysis of overall survival.

AVEO Pharmaceuticals, Inc. - Special Call

To discuss presentation of final results and biomarker analysis from phase 2 study of tivozanib in patients with advanced colorectal cancer

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VPA:GR €1.25 EUR +0.017

VPA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $2.18 USD -0.04
Bristol-Myers Squibb Co $65.00 USD +0.30
Exelixis Inc $2.49 USD -0.08
GlaxoSmithKline SAE £12.00 EGP 0.00
Takeda Pharmaceutical Co Ltd ¥6,111 JPY -134.00
View Industry Companies
 

Industry Analysis

VPA

Industry Average

Valuation VPA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.9x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVEO PHARMACEUTICALS INC, please visit www.aveopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.